Sectoral Asset Management’s Crescent Biopharma CBIO Stock Holding History

Sectoral Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Buy	+121,300	New	+$2.37M	1.52%	26
2019 Q3	–	Sell	-5,528	Closed	-$6.59M	–	73
2019 Q2	$6.59M	Buy	5,528 +48	+0.9%	+$57.4K	0.79%	47
2019 Q1	$6.83M	Buy	+5,480	New	+$6.27M	0.82%	45
2014 Q2	–	Sell	-446	Closed	-$728K	–	68
2014 Q1	$728K	Buy	+446	New	+$540K	0.03%	58

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sectoral Asset Management's CBIO Position: Q2 2026 in Review

Sectoral Asset Management opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 121,300 shares worth $2.18M. The stake represents 1.52% of the portfolio and ranks #26 among its holdings. This is a return to the name: Sectoral Asset Management previously reported a position in CBIO as recently as Q2 2019.

Sectoral Asset Management first reported a position in CBIO in Q1 2014 and has held it in 4 quarters since. The position peaked at $6.83M in Q1 2019. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Sectoral Asset Management held 121,300 shares of Crescent Biopharma worth $2.18M as of Q2 2026.
Crescent Biopharma was a new Sectoral Asset Management position in Q2 2026.
Crescent Biopharma made up 1.52% of Sectoral Asset Management's portfolio in Q2 2026, its #26 holding.
Sectoral Asset Management first reported a position in Crescent Biopharma in Q1 2014 and has held it in 4 quarters since.
Sectoral Asset Management's Crescent Biopharma position peaked at $6.83M in Q1 2019.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.